Long non-coding RNA HIF1A-As2 and MYC form a double-positive feedback loop to promote cell proliferation and metastasis in KRAS-driven non-small cell lung cancer
Name:
37041291.pdf
Size:
11.52Mb
Format:
PDF
Description:
Identified with Open Access button
Authors
Yang, K.Zhang, W.
Zhong, L.
Xiao, Y.
Sahoo, Sudhakar
Fassan, M.
Zeng, Kang
Magee, Peter
Garofalo, Michela
Shi, Lei
Affiliation
RNA Oncology Group, School of Public Health, Lanzhou University, 730000, Lanzhou, People's Republic of ChinaIssue Date
2023
Metadata
Show full item recordAbstract
Lung cancer is the leading cause of cancer-related deaths worldwide. KRAS is the main oncogenic driver in lung cancer that can be activated by gene mutation or amplification, but whether long non-coding RNAs (lncRNAs) regulate its activation remains unknown. Through gain and loss of function approaches, we identified that lncRNA HIF1A-As2, a KRAS-induced lncRNA, is required for cell proliferation, epithelial-mesenchymal transition (EMT) and tumor propagation in non-small cell lung cancer (NSCLC) in vitro and in vivo. Integrative analysis of HIF1A-As2 transcriptomic profiling reveals that HIF1A-As2 modulates gene expression in trans, particularly regulating transcriptional factor genes including MYC. Mechanistically, HIF1A-As2 epigenetically activates MYC by recruiting DHX9 on MYC promoter, consequently stimulating the transcription of MYC and its target genes. In addition, KRAS promotes HIF1A-As2 expression via the induction of MYC, suggesting HIF1A-As2 and MYC form a double-regulatory loop to strengthen cell proliferation and tumor metastasis in lung cancer. Inhibition of HIF1A-As2 by LNA GapmeR antisense oligonucleotides (ASO) significantly improves sensitization to 10058-F4 (a MYC-specific inhibitor) and cisplatin treatment in PDX and KRASLSLG12D-driven lung tumors, respectively.Citation
Yang K, Zhang W, Zhong L, Xiao Y, Sahoo S, Fassan M, et al. Long non-coding RNA HIF1A-As2 and MYC form a double-positive feedback loop to promote cell proliferation and metastasis in KRAS-driven non-small cell lung cancer. Cell death and differentiation. 2023 Apr 11:1-17. PubMed PMID: 37041291. Pubmed Central PMCID: PMC10089381. Epub 2023/04/12. eng.Journal
Cell Death & DifferentiationDOI
10.1038/s41418-023-01160-xPubMed ID
37041291Additional Links
https://dx.doi.org/10.1038/s41418-023-01160-xType
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1038/s41418-023-01160-x
Scopus Count
Collections
Related articles
- Long non-coding RNA HIF1A-AS2 promotes carcinogenesis by enhancing Gli1-mediated HIF1α expression in clear cell renal cell carcinoma.
- Authors: Li X, Wu Y, Xiao Z, Liu Y, Wang C, Zhou L, Yang X
- Issue date: 2024 Jan
- The long noncoding RNA HIF1A-AS2 facilitates cisplatin resistance in bladder cancer.
- Authors: Chen X, Liu M, Meng F, Sun B, Jin X, Jia C
- Issue date: 2019 Jan
- Tetracycline-inducible shRNA targeting antisense long non-coding RNA HIF1A-AS2 represses the malignant phenotypes of bladder cancer.
- Authors: Chen M, Zhuang C, Liu Y, Li J, Dai F, Xia M, Zhan Y, Lin J, Chen Z, He A, Xu W, Zhao G, Guo Y, Cai Z, Huang W
- Issue date: 2016 Jun 28
- HIF1A-AS2 promotes the metabolic reprogramming and progression of colorectal cancer via miR-141-3p/FOXC1 axis.
- Authors: Zhong X, Wang Y, He X, He X, Hu Z, Huang H, Chen J, Chen K, Wei P, Zhao S, Wang Y, Zhang H, Feng B, Li D
- Issue date: 2024 Sep 3
- Antisense Long Noncoding RNA HIF1A-AS2 Is Upregulated in Gastric Cancer and Associated with Poor Prognosis.
- Authors: Chen WM, Huang MD, Kong R, Xu TP, Zhang EB, Xia R, Sun M, De W, Shu YQ
- Issue date: 2015 Jun